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Abstract 
Silicone is an important material family used for various medical implants. It is biocompatible, but 
its bioinertness prevents cell attachment and, thus, tissue biointegration of silicone implants. This 
often results in constrictive fibrosis and implant failure. Bioglass 45S5® (BG) could be a suitable 
material to alter the properties of silicone, render it bioactive and improve tissue integration. 
Therefore, BG micro- or nanoparticles were blended into medical-grade silicone and 2D as well as 
3D structures of the resulting composites were analyzed in oo by a chick chorioallantoic membrane 
(CAM) assay. The biomechanical properties of the composites were measured and the bioactivity 
of the composites was verified in simulated body fluid. The bioactivity of BG-containing 
composites was confirmed visually by the formation of hydroxyapatite through scanning electron 
microscopy as well as by infrared spectroscopy. BG stiffens as prepared non-porous composites 
by 13% and 36% for micro- and nanocomposites respectively. In particular, after implantation for 
7 days, the Young’s modulus had increased significantly from 1.20 ± 0.01 MPa to 1.57 ± 0.03 MPa 
for microcomposites and 1.44 ±  0.03 MPa to 1.69 ± 0.29 MPa to for nanocpmosites.. Still, the 
materials remain highly elastic and are comparably soft. The incorporation of BG into silicone 
overcame the bioinertness of the pure polymer. Although the overall tissue integration was weak, 
it was significantly improved for BG-containing porous silicones (+ 72 % for microcomposites) 
and even further enhanced for composites containing nanoparticles(+ 94 %). These findings make 
BG a suitable material to improve silicone implant properties. 
 
Keywords: Silicone implants, tissue biointegration, in ovo, CAM assay, bioactive glass  
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1. Introduction 
Silicone elastomers are a frequently used material family for the production of medical 
devices and used in implants, such as pacemakers, breast implants and artificial blood 
pumps.1-4 The long-term stability of these implants inside the human body is a crucial factor 
for their success. Adverse events during the lifetime of implants, such as infections or 
fibrotic reactions, are severe clinical problems and affect the quality of life of patients 
significantly.5-6 Silicones were tested for thrombosis, coagulation, platelet activation, 
leukocyte activation, haemolysis, and complement activation in a wide range of possible 
applications and did not show any adverse effects.7 
However, clinicians from different fields, such as cardiac or plastic surgery, are frequently 
forced to exchange failing implants manufactured of silicone elastomers. The material’s 
bioinertness can be the cause of this failure as it does not allow sufficient cell attachment 
and therefore impedes tissue adhesion and implant anchorage.8 This is a particular problem 
for silicone breast implants,  where the lack of cell attachment of the breast tissue to the 
silicone material and continuous micro-movement at the implant(silicone)-tissue interface 
frequently triggers constrictive fibrosis.9 Similarly, percutaneous implants, such as 
ventricular assist device drivelines or catheters, are frequently made of silicone. As the skin 
cannot adhere to the silicone, these devices continuously disrupt the skin’s protective barrier 
against pathogens.10 As a consequence, the skin suffers from continued micro-trauma, 
which (i) compromises the integrity of the silicone-skin interface, (ii) gives an entry point 
for germs and (iii) causes chronical inflammatory reactions of the body.6, 11-12 Biointegration 
of the driveline into the skin by wound healing around the device, formation of an interface 
between the material and tissue, and prevention of  pathogen invasion would be a suitable 
approach to close the protective barrier and stabilize the implant.10 These clinical examples 
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demonstrate the desire of clinicians and patients for a long-term stable silicone-tissue 
connection. Continuous trauma, mechanical irritation, infections and fibrous encapsulation 
would be reduced. 
A suitable material to modify silicone material in order to address the aforementioned 
problems is bioactive glass. This inorganic material can provide silicone with the desired 
bio-integrative properties. Previously, we have shown that the incorporation of bioactive 
glass particles into medical-grade silicone improves the cell proliferation of primary human 
dermal fibroblasts on medical-grade silicone.12 Bioactive glass is an amorphous material, 
which is available in various compositions.13 Its best-known form is Bioglass 45S5® (BG), 
invented by Larry Hench in 1971 with a composition of 45 wt% SiO2, 24.5 wt% Na2O, 
24.5 wt% CaO and 6 wt% P2O5.13-15 While implanted, BG leaches ions into the body fluids 
and has a stimulatory effect on angiogenesis and wound healing.16-18 Additionally, it 
possesses antibacterial properties, which renders it advantageous in contact with soft 
tissue.16, 19 Finally, after transformation to hydroxyapatite (HAp), it enables the bonding to 
collagen. 20 
The study presented here continues on from our report about BG-silicone composites, which 
could not show improved tissue adhesion at first but only bioactivity and improved 
cytocompatibility on smooth samples.12 Here, we report an in ovo evaluation of non-porous 
and porous BG-silicone composites using a chick chorioallantoic membrane (CAM) assay. 
We describe the manufacturing process of porous BG-silicone composites, incorporating 
either micron- or nanosized BG, an in vitro study in simulated body fluid (SBF) and the 
influence of the particles and porosity on the mechanical properties of silicone. The in ovo 
study gives additional information regarding living tissue biointegration of BG-containing 
silicone foams and justifies the use of BG in medical-grade silicone elastomers. 
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2. Materials and Methods 
2.1. Manufacturing of Bioglass 45S5® silicone composites 
Bioglass 45S5® microparticles (mBG) with a supplier-specified mean particle size of 
4.1 µm (d50) were purchased from Schott (mBG, bioactive glass 45S5®, SCHOTT, 
Landshut, Germany). Bioglass 45S5® nanoparticles (nBG) were manufactured by means of 
flame spray synthesis as described earlier by Brunner et al.21 Briefly, the corresponding 
amounts of silicone-, sodium-, calcium- and phosphorous precursors were mixed and 
diluted with tetrahydrofuran (inhibitor-free, Sigma-Aldrich, Buchs, Switzerland) at a 
volumetric ratio of 2:1. The mixture was dispersed in oxygen and ignited in a 
methane/oxygen flame. The nanoparticles were collected on a filter and sieved. 
Six types of materials were manufactured: pure silicone elastomer and silicone elastomer 
containing 5 wt% mBG or 5 wt% nBG. All three compositions were manufactured in 
nonporous as well as in porous form. A medical-grade 2 component platinum addition cure 
silicone elastomer (silicone, Silicone Elastomer A-103, Factor II Inc., Lakeside AZ, USA) 
was purchased. The corresponding amount of BG was mixed with component A of the 
silicone in a dual-axis centrifuge mixer (Speed Mixer DAC 150 FVZ, Hauschild 
Engineering, Hamm, Germany) at 3500 rounds per minute (rpm) for 2 minutes. 
Subsequently, ammonium bicarbonate (NH4HCO3, BioUltra, ≥ 99.5%, Fluka Analytical, 
Steinheim, Germany) was added as a porogen at a concentration of 20 wt% with respect to 
the mass of silicone component A and mixed for 2 min at 3500 rpm, subsequently. The 
corresponding amount of silicone component B was added and mixed for 1 min at 
3500 rpm. The uncured mixture was transferred into a syringe, degassed in a desiccator at 
8 mbar for at least 10 min and transferred to a clean Teflon cylinder (diameter = 30 mm, 
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depth = 40 mm). The silicone was cured in an oven at 200 °C for 2 hours and the porogen 
evaporated simultaneously. 
Additionally, nonporous samples of the same compositions were manufactured. The 
materials were prepared as described earlier.12 Briefly, corresponding amounts of silicone 
component A and BG were mixed in a Speed Mixer and degassed for several times. 
Subsequently, silicone component B was added, mixed, transferred to a syringe and 
degassed to 8 mbar for at least 10 mins. Uncured mixtures were poured into a Teflon form, 
degassed  until all entrapped air bubbles were removed and cured at RT overnight to yield 
a smooth surface. Afterwards, the composites were post-cured for 24 hours at 100 °C. 
Thermogravimetric analysis (TG, Linseis TG/STA-PT1600, Selb, Germany) was used to 
investigate the manufacturing process and assure complete removal of the porogen material. 
Approximately 25 mg samples were heated at a rate of 10 °C min-1 from RT to 200 °C and 
kept for 2 hours. 
2.2. Characterization of the materials 
2.2.1. Particles. nBG, mBG and porogen particles were analyzed by scanning electron 
microscopy (SEM, FEI NovaNanoSEM450, FEI, The Netherlands) after being sputtered with a 
5 nm layer of platinum. A particle size distribution (PSD) of ammonium bicarbonate was measured 
by taking the average diameter of all 298 particles present in a randomly chosen area of the SEM 
sample holder. The particle diameter was calculated by fitting the particles’ appearance in the SEM 
images with an ellipse and taking the average of the major axis and minor axis of each particle as 
the individual particle diameter. 
2.2.2. In vitro analysis using simulated body fluid. In vitro bioactivities of porous samples were 
determined using a SBF assay, prepared according to Kokubo and Takadama with a pH of 7.4.22 
Chemicals with a purity of Ph. Eur. were used for the preparation of SBF. Samples of porous BG-
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silicone composites were cut with a scalpel yielding cubical shapes of approximately 5 mm x 5 mm 
x 5 mm (n = 5). Samples were washed in ethanol (EtOH, purists. p.a., Sigma Aldrich), 
subsequently dried in vacuum overnight at RT and weighted (M0, dry). Samples (approx. 50 mg) 
were immersed in 5 mL of fresh SBF and incubated in a water bath at 37 °C for 4 weeks. SBF was 
exchanged once a week. After 4 weeks, samples were gently dried on paper and weighted (Mt, wet). 
Subsequently, samples were dried in vacuum for 1 week and weighted (Mt, dry). Weight loss (%WL) 
and water uptake (%WA) were calculated with the following formulas:23 
%𝑊𝐿 = %𝑀',)*+ − 𝑀-,)*+𝑀',)*+ .	× 100 
%𝑊𝐴 = %𝑀-,45- − 𝑀-,)*+𝑀6,)*+ .	× 100. 
As prepared and immersed samples were analysed by SEM. Samples were frozen in liquid nitrogen 
and broken for cross-sectional observations.24 Broken samples were mounted on carbon tape on 
the sample holder and sputtered with a 5 nm platinum layer. In vitro bioactivity of samples was 
determined by the formation of hydroxyapatite (HAp), which was identified visually by SEM. 
HAp formation on the composites after immersion in SBF was analyzed using Fourier-transformed 
infrared spectroscopy (Bruker Tensor 27 FT-IR Spectrometer, Etlingen, Germany). Samples were 
burned in an oven at 700°C for 2 hours. The particulate samples were ground at 5 wt% in KBr. The 
IR spectra of the composites after immersion in SBF were measured versus a background of the 
respective composite before immersion in SBF. The spectra were collected in a frequency range of 
500-1300 cm-1 and accumulating 100 scans. The spectra were not base-line corrected and not 
nomralised.  
2.3. Physical properties of the composites 
Porosities of foams were measured by cutting samples to sheets with a thickness of 
approximately 10 mm. Circular pieces of foams with a diameter of 12 mm were punched 
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from the sheets.The thickness of each sample was measured with calipers. Subsequently, 
samples were weighted on a balance. Porosities were calculated by comparing the densities 
of porous composites with the calculated densities of the non-porous samples (n = 4). 
Stiffness of non-porous composites was measured before and after implantation in chicken 
embryos to evaluate the change of stiffness under in ovo conditions (see below) using 
ASTM Norm D412-16. Implanted samples were washed with phosphate buffered saline 
solution (PBS without Ca/ Mg, pH 7.2, Kantonsapotheke Zürich). Composites were cut into 
a rectangular form (length = 20 mm, width = 6 mm, thickness = 3 mm) with a blade and 
sterilized in ethylene oxide. The Young’s modulus was measured using a tensile tester 
(Shimadzu AGS-X, 50 N load cell, Reinach, Switzerland). Samples were placed in the 
sample holder using pressurized air at 5 bar and stretched at a strain rate of 50 mm min-1. 
An initial gauge length of 10 ± 1 mm was used. The Young’s modulus was calculated at 
low strains of 0.05 in the linear regime of stress-strain curve using a tangent approximation. 
The sample sizes for the as prepared and implanted composites were n = 5 and n = 4, 
respectively. 
2.4. In ovo characterization with a chick chorioallantoic membrane (CAM) assay 
2.4.1. Sample preparation. Two different types of samples were prepared for the in ovo CAM 
assay. First, non-porous samples were cut to rectangular shapes (20 x 6  x 3 mm3) with a scalpel in 
order to measure the mechanical properties after implantation. Second, porous samples were 
prepared by cutting the material to circular pieces with a diameter of 5 mm and a thickness of 3 mm 
using a scalpel for measurements of tissue biointegration. Once established that even much larger 
surface area non-porous samples had no tissue integration, comparisons between different porous 
samples were performed with smaller, more typically sized specimens for the CAM assay.25 
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Samples were washed in EtOH, gently wiped on paper and dried in vacuum overnight, 
subsequently. Sterilization was performed by ethylene oxide. 
2.4.2. CAM assay: implantation of the composites onto the CAM. Fertilized Lohman white 
LSL chicken eggs were purchased from Animalco AG, Switzerland, and incubated at 37 °C 
and 65 % relative humidity in an incubator for 3.5 days. For experiments in chicken 
embryos until embryonic day 14 no IACUC approval is required according to Swiss animal 
care guidelines (TSchV, Art. 112). Afterwards, using a drill, a window was created in the 
eggshell after removing 2 mL of albumen. The window was covered with a Petri dish and 
incubated at 37 °C for another 3.5 days as described earlier.26 On incubation day (ID) 7, the 
scaffolds were gently placed on top of the CAM, either without plastic ring for the 
nonporous samples (n = 8 for all groups) or with a plastic ring (diameter = 10 mm) for the 
porous samples (C: n = 5; mBG: n = 6; nBG: n = 11). Finally, the eggs were incubated for 
another 7 days, fixated in 4 % formalin solution in PBS, and incubated at 4 °C overnight. 
Then, the scaffolds were excised, embedded in paraffin, cross-sectioned into 5 µm slices 
and stained with hematoxylin/eosin (H&E). 
2.4.3. Histological analysis. Integration factors for porous scaffolds were determined based 
on semi-quantitative scoring of H&E stained sections. Images were taken at 100x 
magnification using a light microscope (Leica DM 6000 B) equipped with a digital camera. 
In each histological section, five FOVs (Fields of View) were analysed, resulting in n = 15 
for groups mBG and nBG and n = 30 for Control, respectively. The imprint of the scaffold on 
the CAM surface with its indentations was scored as a semi-quantitative tissue integration factor: 
0 = no integration; 1 = slight integration; 2 = good integration and 3 = complete integration. 
Vascularization was assessed in the chorioallantoic membrane beneath each porous scaffold as well 
as 1 cm away from the material as a reference. It was semi-quantitatively scored: 0 = no vessels; 1 
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= very few vessels; 2 = few vessels; 3 = some vessels; 4 = a lot of vessels; 5 = highly vascularized 
(maximum) (for representative examples of each score, see Figure 5f). 
The CAM thickness as well as the layer on top of the CAM (here referred to as collagen over layer) 
were measured below the scaffolds and 1 cm away in the same egg for comparison (here referred 
to as reference zone). 
2.5. Statistical analysis 
Results are given as mean ± standard deviation. Statistical significance was calculated using 
a one-way analysis of variance (ANOVA) with a Bonferroni’s post-hoc correction 
(OriginPro 9.1.0, Origin Lab Corp. Northampton MA, USA). Statistical significance was 
assumed at a p value of p < 0.05. 
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3. Results 
3.1. Particle characterization 
Figure 1 shows the differences of BG micro- and nanoparticles. Microparticles had a shard-
like appearance and a mean particle size of 4 µm as specified by the supplier. In contrast, 
nanoparticles had spherical shapes and an approximate primary particle size of 40-100 nm 
(see supporting information Figure S1). SEM analysis (Figure 1b and S1) revealed fusing 
of the flame-sprayed primary nanoparticles to larger agglomerates with an average 
agglomerate size of approximately 12 µm.12, 21 
Analysis of the porogen (NH4HCO3) showed particles with an average primary particle size 
of 60 µm as seen in the particle size distribution of Figure 1d. NH4HCO3 contained particles 
of up to 400 µm in diameter. SEM images of the NH4HCO3 particles depicted non-spherical, 
non-agglomerated particles with different forms and softened edges. 
3.2. Morphology of porous micro- and nanocomposites 
The samples (micro- and nanocomposites) were highly porous with measured porosities in 
the range of 76 to 82 %. Pure silicone foam had a porosity of 81.6 ± 1.4% (n = 4), while the 
values for micro- and nanocomposites were 77.3 ± 1.4% (n = 4) and 75.6 ± 1.2% (n = 4), 
respectively. The samples had comparable pore sizes of up to 1 mm in diameter and were 
interconnected. 
3.2.1. Thermogravimetric analysis. Thermogravimetric analysis revealed complete dissociation 
of NH4HCO3 under the manufacturing conditions of 200 °C for 2 hours without traces. Complete 
removal of the porogen from the silicone at the applied curing conditions were shown. Also, pure 
BG micro- and nanoparticles as well as pure silicone were not affected by the applied temperatures. 
3.2.2. In vitro bioactivity study of porous samples. The bioactivity study in SBF showed the 
formation of HAp on and within the porous composites, incorporating BG. As seen in Figures 2e 
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and 2f, the HAp is formed evenly on the surface of the foams and within the pores. The presence 
of HAp after incubation in SBF was proven by its typical crystalline appearance in Figures 2h and 
2i.27 The presence of HAp was confirmed by FT-IR as for nano- and microcomposites, the 
characteristc band for CO32- in carbonated apatites at 870 cm-1 was present.28-29 The FT-IR 
spectrum of the nanocomposite also showed the characteristic double peak for the characteristic 
bending mode of the P-O-P bond in HAp at 570 cm-1 and 600 cm-1 (Figure S4).29-30 The foaming 
procedure of silicone with NH4HCO3 did not have an effect on the bioactivity of the composites.  
Comparing the samples before (Figures 2a-2c) and after incubation in SBF (Figures 2d-2f) no 
changes of the general geometry of the pores were noted. The pore structure under simulated 
implanted conditions remained intact. Only the BG containing foam’s surface structure seemed to 
be affected by the conditions in the SBF. The results of %WL and %WA are provided in the 
supporting information in Figure S2. 
3.3. Mechanical properties 
The stiffness of non-porous composites was affected by the modification with nBG particles. 
Incorporating solid nanoparticles resulted in significantly stiffer materials compared to pure 
silicone (p < 0.05), while microparticles did not increase the stiffness significantly compared to 
pure silicone (p = 1) (Figure 4). After implantation in chicken embryos the Young’s modulus of 
pure silicone did not change compared to as prepared silicone (p = 1), while the ones of the micro- 
and nanocomposites changed significantly to its corresponding as prepared counterparts 
(p < 7.8*10-4). Generally, incorporated BG particles stiffened silicone elastomers significantly 
in ovo compared to pure silicones (p < 1.4*10-5). 
3.4. In ovo CAM assay 
Although different degrees of adhesion of the CAM were qualitatively distinguished for non-
porous scaffolds, with increasing adhesion in the order of Control < mBG < nBG, semi-quantitative 
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scoring was only performed for porous scaffolds. During histological processing and cutting, 
materials were separated from the CAM surface. However, it was clearly found that the shape of 
the scaffold surface was reflected and similar to the shape of the CAM surface – the higher the 
integration the higher this similarity. Hence, scoring was performed and mBG and nBG were better 
integrated than pure silicone; with nBG even significantly better than mBG (Figure 5 c and d). 
Moreover, vascularization was semi-quantitatively scored beneath each porous scaffold. It was 
found that pure silicone evoked a significantly higher vessel density below the material as 
compared to the BG containing materials, for which mBG and nBG were not significantly different. 
In the reference zone, pure silicone evoked significantly higher vessel density than nBG. 
In addition, CAM swelling was assessed by measuring the thickness (Figure S3a). The CAM was 
significantly thicker for BG containing materials compared to pure silicone, but not significantly 
different for mBG and nBG; the same was found for the collagen layer on top of the CAM (Figure 
S3b). 
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4. Discussion 
We successfully showed that manipulating silicone by blending Bioglass 45S5® particles into 
silicone and forming a 3D-structure significantly improved tissue integration of the elastomer in 
an in ovo CAM assay. The simple manufacturing process of blending with BG particles and 
foaming with ammonium bicarbonate proved to be successful and reliable. Verified by HAp 
formation in an in vitro SBF assay we illustrated the bioactivity of the materials. A biomechanical 
analysis showed mechanical integrity of BG/silicone composites with expectable, but little 
stiffening under implanted in ovo conditions. 
In order to address the adverse events of silicone implants, caused by the material’s bioinertness, 
we decided to investigate the in ovo tissue biointegration of elastomeric silicone composites. The 
composites  had been modified in their bulk by blending bioactive particles rather than modifying 
only the composites’ surfaces. Ross et al. tackled the problem of insufficient tissue adhesion to 
peritoneal dialysis catheters by coating silicone tubing with melt-derived 45S5 Bioglass® particles. 
These particles were up to 125 µm in diameter, and the tubing was subcutaneously implanted in a 
rat model.8 The BG coated sections were palpably fixed to the soft tissues as compared to the 
uncoated silicone, which did not show any adherence to the surrounding tissue.8 In contrast to a 
coating, the goal of this study was to investigate, whether blending of BG particles into the material 
could have similar positive effects of tissue integration in silicone implants. Comparable attempts 
had been undertaken by Wang et al., however using rigid high density polyethylene (HDPE) rather 
than soft silicone rubber.31 The authors blended Bioglass® microparticles (46 µm) into HDPE and 
could prove bioactivity in SBF, but did neither show an in vitro cell assay on the material nor any 
in vivo results.31 In close similarity to the work of Wang et al., we decided to investigate the 
potential of blending bioactive micro- and nanoparticles into silicone in order to improve tissue 
adhesion of this type of soft, elastomeric and medically relevant implant material. 
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Manufacturing. The manufacturing process of blending BG45S5® particles into the elastomer 
prior to cross-linking was easy and versatile. We chose micro- and nanoparticles in order to 
compare the influence of the particle size, i.e. its surface area on the manufacturing process of the 
composites, its mechanical properties and its in ovo tissue integration. In contrast to Wang et al., 
who investigated particle volume fractions of up to 40 %, we limited the weight fraction of the 
bioactive particles to 5 wt% (2.14 vol%), because when using the same particles as previously 
reported  it was shown that the maximum amount of nanoparticles to be incorporated into silicone 
elastomers is limited.12, 31 This might be due to an incompatibility of silicone with BG, which is 
particularly enhanced for nanoparticles with a larger surface area as compared to microparticles 
with comparably small surface to volume ratios. Alternatively, also the nanoparticle-based 
inhibition of the platinum catalyst for the curing reaction of the silicone seems reasonable. This 
was reported earlier by Fahrni et al. for iron oxide nanoparticles in polydimethylsiloxane 
(PDMS).32 The incorporation of larger amounts than 10 wt% nBG was not possible and already at 
this weight fraction, the mechanical integrity of the composites in vitro was significantly 
compromised.12 Thus, we decided to limit our study to 5 wt% composite-loading. 
The foaming procedure using ammonium bicarbonate in silicone elastomers was adapted from Lin 
et al. and Mac Murray et al..33-34 NH4HCO3 was chosen, because it decomposes to the gaseous 
molecules ammonia, carbon dioxide and water above a temperature of approximately 60 °C 
(Figure 3). The gases formed the pores within silicone and were removed completely from the 
composite foams without residues.34 A temperature of 200 °C was chosen, because we noted that 
for lower values, the porogen inhibited curing of the two-component silicone. This coincides with 
literature, which reports that NH4HCO3 inhibits the platinum catalyst in addition-cured PDMS 
resins.34-35 We could overcome this problem by applying the comparably high temperature of 
200 °C, which resulted in simultaneous curing of silicone and porogen removal. We did not apply 
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a pre-curing reaction at low temperatures before the removal of the porogen at elevated 
temperatures. In contrast to the production process of the porous samples, the elevated curing 
temberature of 200 °C was not required for the production of non-porous samples due to the 
absence of NH4HCO3. Thus, a lower temperature of 100 °C was chosen.  
Composites. The foaming resulted in an open-pore structure, as already reported by Mac Murray 
et al., even though it is difficult to verify this with the SEM images presented in Figure 2.34 
However, we could show the interconnectivity of the pores by placing porous samples on absorbent 
paper and putting an EtOH drop on the samples. After a short period of time the absorbent paper 
was wetted by the EtOH, having passed through the porous sample. This verified the 
interconnectivity of the pores. Also, the presence of the BG particles did not seem to have a 
significant impact during the foaming of the composites, as the 3D-structure of all samples seemed 
to be comparable (Figure 2) as well as the porosity of approximately 80 % for each material. 
The in vitro SBF assay proved the bioactivity of the porous and BG-containing composites, verified 
visually by HAp formation in the SEM images of the samples after incubation (Figure 2) and 
compared with previously published SEM images of HAp.27 HAp formation was also validated by 
FTIR (Figure S4). The presence of HAp is crucial for the formation of a stable interface between 
the implant and soft tissue as it forms a bond to collagen fibrils.14 Porous control samples without 
BG did not show any HAp, which verified the BG inflicted bioactivity of the composites. Also, it 
proved that using NH4HCO3 as porogen does not affect the bioactivity of the BG andthe 
composites. The presence of HAp, even deeper within the porous structure, could be verified. This 
served as a first approximation for possible tissue ingrowth into the 3D structure and, thus, as an 
approximation, whether a more stable 3D-fascilitated interface between the composite and the 
tissue can be achieved. 
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Mechanical properties. Incorporating BG into the non-porous elastomeric polymer resulted in a 
stiffening of the composites as compared to pure silicone (Figure 4), which coincides with theory 
and previous reports.36 Rigid particles have larger moduli than silicone and when blended into the 
elastomer, increased the moduli thereof. The Young’s modulus generally did not depend on 
particle/matrix interactions, because it was measured in the small strain regime, where no 
particle/matrix-debonding occurred.36 Classical theories on the Young’s modulus only give a 
dependency of the filler volume fraction and not filler diameter.36-38 However, as also shown in our 
results, a larger Young’s modulus was measured with a decreasing filler in primary particle size. 
This has been reported earlier in multiple studies and is being attributed to a critical particle size.36 
After implantation, the particle-loaded composites had significantly increased moduli, which had 
been reported earlier by us in an in vitro assay.12 We attributed this to true reinforcement by nBG. 
Finer dispersion of the smaller nanoparticles formed crystalline and solid HAp across the bulk of 
the silicone in vitro, which increased the stiffening of the composites more than for mBG 
containing composites. HAp could only be formed very localized at the larger BG locations in 
microcomposites, thus not stiffening the material as much as in nanocomposites.12, 39 We assume 
that this explanation also holds for a biomechanical in vivo assay. 
CAM assay. The CAM assay is an easy and fast assay often used in the field of tissue engineering 
and regenerative medicine.40It allows short-term determination of a biomaterial’s biocompatibility 
and integration into the chorioallantoic membrane of the chicken embryo.41 First, we tested 
biointegration of non-porous silicone and composites during the 7-day incubation in the CAM 
assay. Although biointegration was weak for all the three materials tested, there was a qualitative 
difference between silicone and the composites during removing them from the CAM. While pure 
silicone rubber could easily be separated from the CAM surface by tweezers (tip width: 1 mm, 
approximate pulling force: 120 mN), because there was a visible gap between silicone and the 
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CAM, removal of mBG and nBG composites was more difficult, caused by the adhesion of the 
materials’ flat surface to the membrane.  
Secondly, we investigated the biointegration of porous silicone and composites. Confirming that 
pores support biocompatibility and biointegration of many biomaterials42, we found that porous 
materials were better integrated compared to non-porous materials (data not shown). All materials 
(silicone, mBG and nBG) were not removable by using tweezers. Whilst overall integration 
remained poor in comparison to other materials, introduction of porosity significantly improved 
biointegration compared to the non-porous silicone and composites.  After formalin fixation, the 
tissue-material construct was cut out as a whole and processed for histological analysis. Only 
during cutting with a microtome, the materials were separated from the CAM surface. However, 
the higher the tissue integration before cutting, the higher the similarity of the imprint on the CAM 
surface. Hence, we semi-quantitatively scored the integration (Figure 5). Obviously, pure silicone 
was less well integrated than the composites. The presence of BG, either micron-sized or 
nanosized, improved the quality of biointegration. When mBG was compared to nBG porous 
composites, there was even a better integration for the nanocomposites as compared to the 
microcomposites. Such findings stand in accordance with a study by Chan and coworkers where 
an inert polyetheretherketone (PEEK) was reinforced with HAp nanoparticles and compared to 
PEEK with HAp microparticles. They reported that nanocomposites showed not only improved 
mechanics but also an excellent biocompatibility and integration compared to the 
microcomposites.43 
As for the vascularization of the CAM below the scaffolds, we found a higher vessel density for 
pure silicone as compared to the BG-containing materials which were both similarly vascularized. 
It might be speculated whether the bioglass or its transformation product hydroxyapatite decreased 
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the angiogenic response towards the BG/silicone scaffolds – the two components have been 
reported to act differently towards neovascularization.44-45 
 
Limitations of the study. This study has several limitations. The CAM assay fulfills only gives 
information about the materials’ short-term behavior in implanted conditions, meaning 
implantation for 7 days. It cannot predict the materials’ properties, when it has to fulfill a certain 
function, in this case the formation of a stable silicone/skin interface to prevent infection. It gives 
important data on tissue adhesion and biocompatibility but only more complex animal studies will 
give certainty on the material capacity to fulfill a certain function. 
5. Conclusion 
The incorporation of BG45S5® into medical-grade silicone elastomer and forming a 3D-
structure with a porogen significantly improves the tissue integration of the material in ovo. 
nBG/silicone composites have significantly improved biointegration compared to 
mBG/silicone composites. Either type of BG (micro or nano) improves the biointegration, 
compared to pure silicone. All BG-containing silicones show bioactivity also deeper within 
the pores. The pure incorporation of BG45S5®, irrespective of the particle size of the 
bioactive material and keeping a 2D geometry, does not yield stable tissue adhesion in a 7-
day in ovo CAM assay. Whether a 2D material can form a more stable skin-silicone 
interface with improved healing in a possible application in percutaneous devices remains 
unknown, however is rather unlikely. The CAM assay showed the requirement for 3D 
porous structures to measure short-term improvements in tissue adhesion. The need for a 
3D structure complicates the manufacturing procedure, especially when it has to be applied 
to a specific, existing implant with a required geometry. Still, it remains comparably easy. 
The mechanical properties prove stable materials within the measured time frame. 
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Summarizing, the manufacturing of the composites by simple blending of bioactive 
particles and forming a 3D structure in the clinically relevant material silicone is very easy, 
the in ovo results prove better tissue integration compared to pure silicone and the 
mechanical integrity remains intact. 
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Figure legends 
Figure 1. Scanning electron microscopy (SEM) images of Bioglass 45S5® microparticles (a) and 
nanoparticles (b). (c) and (d) depict the SEM image and the particle size distribution of ammonium 
bicarbonate, respectively. 
 
Figure 2. Scanning electron microscopy (SEM) images of Bioglass®/silicone composites before 
and after incubation in simulated body fluid (SBF) for 4 weeks. (a), (b) and (c) show pure silicone 
foam, silicone incorporating 5 wt% micron sized Bioglass® (BG) and silicon incorporating BG 
nanoparticles (5 wt%) as prepared, while (d), (e) and (f) show the respective samples after 
incubation in SBF. (g), (h) and (i) are close-up images of the samples after incubation in SBF and 
show the structure of hydroxyapatite in the case of microcomposites (h) and nanocomposites (i). 
 
Figure 3. Thermogravimetric analysis of the manufacturing process. 
 
Figure 4. Influence of in ovo environment in chicken embryos in a chick chorioallantoic membrane 
(CAM) assay on the mechanical properties of non-porous Bioglass 45S5®/silicone elastomer 
composites. (a) gives the stress-strain curve in the small strain region and (b) gives the Young’s 
modulus of the materials as prepared (n = 5) and after implantation in chicken embryos for 7 days 
(post in ovo, n = 4). (control: pure silicone elastomer; mBG: silicone elastomer with 5 wt% 
Bioglass® (BG) microparticles; nBG: silicone elastomer with 5 wt% BG nanoparticles; *: 
significant differences for p < 0.05) 
 
Figure 5. Results and analysis of the in ovo chick chorioallantoic membrane (CAM) assay of 
porous and non-porous Bioglass 45S5®/silicone elastomer composites. (a) shows the samples on 
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the CAM (left: non-porous, right: porous). (b) exemplifies imprints left behind by the scaffolds on 
the CAM. (c) shows the measured integration factor in porous composites with weight 
concentrations of 5 wt% microparticles (mBG) and 5 wt% nanoparticles (nBG). (d) defines the 
integration factor based on histological cuts of the tissue (for control and mBG: n = 15 FOVs; for 
nBG: n = 30 FOVs). The scores are defined as: 0 = no integration; 1 = slight integration; 2 = good 
integration and 3 = complete integration. (e) shows the semi-quantitatively determined 
vascularization extent below the scaffods in the chorioallantoik membrane with 0 = no vessels; 1 
= very few vessels; 2 = few vessels; 3 = some vessels; 4 = a lot of vessels; 5 = highly vascularized  
(*: significant differences for p < 0.05; ***: significant differences for p < 0.0001), and (f) defines 
the vascularization scores by representative histological sections. 
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1. Scanning election microscopy images   
 
 
 
Figure S1. Scanning election microscopy image of nanosized Bioglass 45S5® particles.  
 
2. Weight loss and water uptake of samples 
 
 
 
Figure S2. Depiction of the weight loss (a) and water uptake (b) of the porous pure silicone (control), 
porous silicone, containing 5 wt% Bioglass 45S5® microparticles (mBG) and porous silicone, 
containing 5 wt% Bioglass 45S5® nanoparticles (nBG). (*: significant differences for p < 0.05) 
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3. CAM thickness and collagen over layer 
 
 
 
Figure S3. CAM thickness below the porous scaffolds and 1 cm away from the scaffolds (reference 
zone) (a) and collagen over layer as a response towards the on-planted scaffolds (b). (*: significant 
differences for p < 0.05; ***: significant differences for p < 0.0001) 
 
 
4. FT-IR assessment 
5.  
Figure S4. FTIR spectra of nano- and microcomposites after immersion in simulated body fluid (SBF) 
for four weeks. As background the respective materials before immersion in SBF were used. Both 
composites show the characteristic peak of the CO32- group in carbonated apatite, which serves as the 
proof for hydroxyapatite formation.  
 
